LMNL — Liminal BioSciences Share Price
0.000.00%
Last trade - 00:00HealthcareSpeculativeMicro Cap
- $27.62m
- $14.21m
- CA$0.40m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.23 | ||
| Price to Tang. Book | 1.38 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 66.61 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -103.45% | ||
| Return on Equity | -83.59% | ||
| Operating Margin | -5788.83% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | 24.63 | 0.74 | 0.72 | 0.64 | 0.4 | n/a | n/a | -59.99% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Liminal BioSciences Inc. is a Canada-based development-stage biopharmaceutical company. The Company is focused on developing distinctive novel small molecule therapeutics for inflammatory, fibrotic and metabolic diseases using its drug discovery platform. The Company is developing Selective G-protein coupled receptor 84 (GPR84) Antagonist and Oxo-eicosanoid receptor 1 (OXER1) Antagonist. Its GPR84 is a pro-inflammatory target primarily expressed on cells associated with the immune system and its expression levels increase significantly during periods of inflammatory stress. Inhibition of GPR84 can inhibit neutrophil and macrophage migration and reduce cytokine release. GPR84 antagonist program is at the pre-clinical-stage. The OXER1 is a G protein-coupled receptor (GPCR) that is highly selective for 5-Oxo-eicosatetraenoic acid (5-oxo-ETE), a potent human eosinophil chemo-attractant. OXER1 antagonist program is in the pre-clinical-stage.
Directors
- Aleksander Krstajic NEC (50)
- Patrick Sartore PRE (45)
- Bruce Pritchard CEO (47)
- Murielle Lortie CFO (51)
- Martin Leclerc CHO (57)
- Marie Iskra GCN (44)
- Moira Daniels OTH (58)
- Simon Best LED (63)
- Eugene Siklos DRC
- Gary Bridger IND (58)
- Neil Klompas IND (50)
- Timothy Wach IND (59)
- Last Annual
- December 31st, 2022
- Last Interim
- March 31st, 2023
- Incorporated
- October 14th, 1994
- Public Since
- July 5th, 2019
- No. of Employees
- 43
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 3,249,534
- Address
- 231 Dundas Street East, BELLEVILLE, K8N 1E2
- Web
- https://liminalbiosciences.com/
- Phone
- +1 4507810115
- Contact
- Shrinal Inamdar
- Auditors
- Ernst & Young LLP
Upcoming Events for LMNL
Q3 2023 Liminal BioSciences Inc Earnings Release
Similar to LMNL
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Aceragen
NASDAQ Capital Market
Acer Therapeutics
NASDAQ Capital Market
FAQ
What is the Liminal BioSciences share price?
As of Today at 01:13 UTC, shares in Liminal BioSciences are trading at $8.36. This share price information is delayed by 15 minutes.
How has the Liminal BioSciences share price performed this year?
Shares in Liminal BioSciences last closed at $8.36 and the price had moved by +95.83% over the past 365 days. In terms of relative price strength the Liminal BioSciences share price has outperformed the S&P500 Index by +68.12% over the past year.
What are the analyst and broker recommendations for Liminal BioSciences?
The overall consensus recommendation for Liminal BioSciences is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Liminal BioSciences dividend yield?
Liminal BioSciences does not currently pay a dividend.
Does Liminal BioSciences pay a dividend?
Liminal BioSciences does not currently pay a dividend.
When does Liminal BioSciences next pay dividends?
Liminal BioSciences does not currently pay a dividend.
How do I buy Liminal BioSciences shares?
To buy shares in Liminal BioSciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Liminal BioSciences?
As of the previous close price of $8.36, shares in Liminal BioSciences had a market capitalisation of $27.23m.
Where are Liminal BioSciences shares listed?
Here are the trading details for Liminal BioSciences:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: LMNL
What kind of share is Liminal BioSciences?
Based on an overall assessment of its quality, value and momentum Liminal BioSciences is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Liminal BioSciences share price forecast for 2023?
The analyst consensus target price for shares in Liminal BioSciences is $7.46. That is 10.82% below the last closing price of $8.36.
Analysts covering Liminal BioSciences currently have a consensus Earnings Per Share (EPS) forecast of -CA$11.08 for the next financial year.
What is the trend in the Liminal BioSciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Liminal BioSciences. Over the past six months, its share price has outperformed the S&P500 Index by +83.28%.
As of the last closing price of $8.36, shares in Liminal BioSciences were trading +53% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Liminal BioSciences PE Ratio?
The Liminal BioSciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $8.36.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Liminal BioSciences?
Liminal BioSciences' management team is headed by:
- Aleksander Krstajic - NEC
- Patrick Sartore - PRE
- Bruce Pritchard - CEO
- Murielle Lortie - CFO
- Martin Leclerc - CHO
- Marie Iskra - GCN
- Moira Daniels - OTH
- Simon Best - LED
- Eugene Siklos - DRC
- Gary Bridger - IND
- Neil Klompas - IND
- Timothy Wach - IND